An Analysis of Monitoring Solutions for CAR T Cell Production
- PMID: 40365510
- PMCID: PMC12073936
- DOI: 10.1049/htl2.70012
An Analysis of Monitoring Solutions for CAR T Cell Production
Abstract
The chimeric antigen receptor T cell (CAR T) therapy has shown remarkable results in treating certain cancers. It involves genetically modifying a patient's T cells to recognize and attack cancer cells. Despite its potential, CAR T cell therapy is complex and costly and requires the integration of multiple technologies and specialized equipment. Further research is needed to achieve the maximum potential of CAR T cell therapies and to develop effective and efficient methods for their production. This paper presents an overview of current measurement methods used in the key steps of the production of CAR T cells. The study aims to assess the state of the art in monitoring solutions and identify their potential for online monitoring. The results of this paper contribute to the understanding of measurement methods in CAR T cell manufacturing and identify areas where on-line monitoring can be improved. Thus, this research facilitates progress toward the development of effective monitoring of CAR T cell therapies.
Keywords: CAR T cell therapy; advanced therapy medicinal product (ATMP); monitoring; on‐line measurement.
© 2025 The Author(s). Healthcare Technology Letters published by John Wiley & Sons Ltd on behalf of The Institution of Engineering and Technology.
Conflict of interest statement
The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures



Similar articles
-
[CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].Internist (Berl). 2021 Apr;62(4):449-457. doi: 10.1007/s00108-021-00953-x. Epub 2021 Feb 15. Internist (Berl). 2021. PMID: 33590292 Review. German.
-
Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group.Bone Marrow Transplant. 2023 Oct;58(10):1069-1074. doi: 10.1038/s41409-023-02072-7. Epub 2023 Aug 1. Bone Marrow Transplant. 2023. PMID: 37528237 Review.
-
Better by design: What to expect from novel CAR-engineered cell therapies?Biotechnol Adv. 2022 Sep;58:107917. doi: 10.1016/j.biotechadv.2022.107917. Epub 2022 Feb 9. Biotechnol Adv. 2022. PMID: 35149146 Review.
-
Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility.Int J Mol Sci. 2024 Sep 26;25(19):10365. doi: 10.3390/ijms251910365. Int J Mol Sci. 2024. PMID: 39408696 Free PMC article. Review.
-
CAR-T cell therapies: patient access and affordability solutions.Future Sci OA. 2025 Dec;11(1):2483613. doi: 10.1080/20565623.2025.2483613. Epub 2025 Mar 29. Future Sci OA. 2025. PMID: 40156283 Free PMC article. Review.
References
-
- National Cancer Institute . CAR T Cells: Engineering Immune Cells to Treat Cancer. 23.10.2023, https://www.cancer.gov/about‐cancer/treatment/research/car‐t‐cells. Accessed 24 Oct 2023.
-
- Markarian J., “Industry 4.0 in Biopharmaceutical Manufacturing,” BioPharm International 31, no. 7 (2018): 36–38.
Publication types
LinkOut - more resources
Full Text Sources